antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for antihemophilic factor

a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia A

References in periodicals archive ?
In addition, it had a longer half-life than Advate, which could potentially reduce the frequency of injections needed by hemophilia patients.
Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment.
The product was well tolerated and demonstrated a prolonged half-life compared to Advate (anti-haemophilic factor recombinant, plasma/albumin-free method, rFVIII) by US-based Baxter International Inc (NYSE: BAX).
This growth was driven by double-digit increases across all product categories, including record sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, which exceeded $1.
Driving this performance was robust growth in demand, particularly in the United States, for ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], and GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)], as well as other plasma-based therapeutics including FEIBA, an inhibitor bypass therapy, and albumin.
Contract award notice: sf a t ea Advate, e adasa apates dses p das (.
The product is built on the full-length ADVATE molecule, a treatment for hemophilia A already in use for more than 13 years.
Continued adoption of Baxter's advanced recombinant therapy, Advate, largely was responsible for generating $2 billion in recombinant product sales last year, a 5 percent increase compared with the $1.
This growth was driven by record sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, antibody therapy products, including GAMMAGARD LIQUID(TM) [Immune Globulin Intravenous (Human)] (IVIG) 10% Solution for the treatment of primary immunodeficiencies, specialty plasma therapeutics and biosurgery products.
With our focus on the needs of the hemophilia patient community, Baxter screened more than 100 molecules over several years and has selected one that has the potential to maintain the safety profile and meaningfully extend the half-life of ADVATE to allow for less frequent dosing.
Contract award notice: psf a t pea advate e dadasa dapates dses p das dddpd.
The company said ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is the only extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].
In the United States and Canada, Baxter also launched Baxject II, a needleless transfer device with built-in filters for Advate.
Sales growth in this business was driven by a 15 percent increase in the recombinant business, including $162 million of sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A.
Secondary endpoints included response to treatment of bleeding episodes and the pharmacokinetics of rFVIIIFc versus Advate.